Second primary malignancies (SPMs) are one of the most critical problems in treating head and neck cancer patients. Our hospital had 742 patients with a diagnosis of malignant head and neck tumors during the five-year period from 2002 to 2006. In this study, we analyzed 360 of those patients who were assumed to have risk factors such as alcohol and tobacco use: 106 oral, 120 laryngeal, 50 oropharyngeal and 84 hypopharyngeal cancer patients. Synchronous SPMs are defined as second cancers diagnosed at the same time or within 6 months of the diagnosis of the index head and neck cancers. There were 4 (3.8%) and 11 (10.4%) oral cancer patients, 11 (8.3%) and 8 (5.8%) laryngeal cancer patients, 7 (14.0%) and 4 (8.0%) oropharyngeal cancer patients, and 30 (28.6%) and 7 (8.3%) hypopharyngeal cancer patients with synchronous and metachronous SPMs, respectively. The number of metachronous patients with synchronous SPMs tended to increase during this time period. The frequencies of SPMs in oropharyngeal and hypopharyngeal cancer patients are similar to those in oral and laryngeal cancer patients. Notably, the most frequent SPMs are upper gastrointestinal tract cancers in Japan, compared to lung cancers in Europe. The five-year overall survival rate of patients with synchronous SPMs was significantly poorer than that of patients without any other tumor except for the index cancer, according to the Kaplan-Meier analysis. In conclusion, searching for SPMs in the upper gastrointestinal tract is a critical issue in head and neck cancer patients in Japan.
Squamous cell carcinoma of the head and neck is the sixth most common cancer worldwide and approximately 600,000 patients develop this type of cancer each year around the world. Despite marked improvements in locoregional control of head and neck squamous cell carcinomas over the past several decades, the overall survival rate of the patients has not changed (Pisani et al. 1999; Parkin et al. 2005) . One major reason for the lack of improved overall survival of patients with head and neck cancers is the increased risk of developing a second primary malignancy (SPM). Most SPMs originate independently from the index cancers because these tumors are not clonally related as proven by genetic examination (Califano et al. 1999; Shiga et al. 2003) . It is thought that this different clonal origin of SPMs results in treatment difficulties. There are two types of SPMs, metachronous and synchronous, and some patients have both types of SPMs. SPMs are critical problems that must be considered to treat patients with head and neck carcinomas. Such treatment happens to be very difficult in some cases because of the advanced stage of the disease and/or difficulties in the management of treatment strategies and timing especially when they have synchronous SPMs. It is well known that smoking and alcohol use are two major risk factors for head and neck cancers and they are also thought to be risk factors for SPMs. Even if treatment for head and neck cancer is successful and the clinical response period appears to be continuing, prognoses may be restricted by SPMs.
We have reviewed our patients with SPMs over a 5 year period and discuss their diagnoses and clinical features.
Patients and Methods
There were 1,214 tumor patients who had been admitted to the Department of Otolaryngology-Head & Neck Surgery at Tohoku University Hospital during the 5-year period from 2002 to 2006, and the overall number of admissions was 1,584 cases. Of those patients, 931 (including 742 malignant tumor cases) underwent radical therapy including surgery, radiation therapy and/or chemotherapy.
In this study, we examined 360 patients with head and neck cancers who were assumed to have some additional risk factors such as alcohol and tobacco use. These patients were diagnosed and treated at the Tohoku University Hospital from 2002 to 2006. There were 106 oral, 120 laryngeal, 50 oropharyngeal and 84 hypopharyngeal cancer patients (Table 1) . Synchronous SPMs are defined as second cancers diagnosed at the same time or within 6 months of the diagnosis of the index head and neck cancers. If they are only diagnosed after 6 months, they are considered metachronous SPMs under criteria of Warren and Gates (Warren and Gates 1932) .
The study design was a retrospective chart review of these patients. This study was approved by the institutional review board and written informed consents were obtained from all patients. Statistical analyses of the data were performed using the χ 2 -test. The Kaplan-Meier method was used to calculate the survival rates of the patients and the Log-rank test was used to analyze significance.
Whole body examination was conducted for head and neck cancer patients before treatment and consisted mainly of 18 F-fluorodeoxy glucose-positron emission tomography (FDG-PET) and upper gastrointestinal (GI) endoscopic examination with lugol chromoendoscopy. We used FDG-PET to follow up the patients after initial treatment of index head and neck cancers at least once a year to detect recurrence and/or metachronous SPMs.
Results
We analyzed first whether the incidence of synchronous SPMs in head and neck cancer patients has been increasing or not during this time period. The numbers of patients with synchronous SPMs were 6 (8.5%), 8 (9.8%), 6 (10.9%), 10 (15.4%) and 15 (17.2%) in 2002, 2003, 2004, 2005, and 2006 , respectively ( Fig. 1 ). On the other hand, the numbers of patients with a prior history of other malignancies were 14 (19.7%), 18 (22.0%), 6 (10.9%), 11 (16.9%) and 18 (20.7%), respectively. The numbers of patients without synchronous SPMs or a prior history of malignancies were 51 (67%), 58 (70%), 51 (85%), 48 (66%) and 66 (69%) in those years respectively. These data suggest that the number of patients with a prior history of malignancies was almost stable, while the number of patients with synchronous SPMs increased slightly during the same time period.
Of the 106 oral cancer patients, 4 had synchronous SPMs, which is equivalent to 3.8% of the patients. There were 21 prior histories of another malignancy and two of the patients had double and triple malignancies. Synchronous SPMs were one each in the colon, the stomach, the oral cavity and the lung. The main sites of prior malignant tumors were the colon and the oral cavity (Table  2 ). There were 5 patients with colon cancer, 5 with oral cancer, 3 with oropharyngeal cancer and 2 with breast cancer. There were 5 other cancers in the esophagus, urinary bladder, uterus, hypopharynx and occult neck. There was also one brain tumor. After treatment of the index head and neck cancers, metachronous SPMs were observed in 11 patients, and they included 4 colon, 2 lung, 3 oral, 1 esophageal and 1 gastric cancers.
Of the 120 cases of laryngeal cancer patients, 11 had synchronous SPMs, which is equivalent to 8.3% of the patients. Synchronous SPMs included 6 in the esophagus, 2 in the stomach, 2 in the oral cavity and 1 in the lung. There were 19 prior histories of other malignancies and 1 patient had double malignancies. The main site of the prior malignancies was the stomach (Table 3 ). There were 6 patients with gastric cancer, 2 with esophageal cancer, 2 with lung cancer, 2 with prostate cancer and 2 with oral cancer. There were 4 other cancers in the colon, liver, epipharynx and skin. There was also one brain tumor. After treatment of the index head and neck cancers, there were 8 metachronous SPMs. Three of the patients had lung cancers and other cancers were observed in the esophagus, abdominal cavity, urinary bladder and nasal cavity (Table  3 ). There was one patient diagnosed with acute myeloid leukemia.
Of the 50 cases of oropharyngeal cancer patients, 7 had synchronous SPMs, which is equivalent to 14.0% of the patients. Synchronous SPMs included 2 in the esophagus, 2 in the stomach, 2 in the oropharynx and one in the lung. There were 15 prior malignant tumors and there were (31) number of the tumors (number of the patients) 2 patients with double malignancies and 1 patient with triple malignancies. The main sites of the prior tumors were the oral cavity followed by the esophagus (Table 4 ). There were 7 patients with oral cancer and 3 patients with esophageal cancer. There were 5 other cancers in the stomach, lung, epipharynx, oropharynx and hypopharynx. There were 4 metachronous SPMs in the stomach, colon and oropharynx after treatment of the index head and neck cancers.
Of the 84 cases of hypopharyngeal cancer patients, 24 had 30 synchronous SPMs, which is equivalent to 28.6% of the patients. Synchronous SPMs included 16 in the esophagus, 4 in the stomach, 3 in the oropharynx, 3 in the thyroid, 2 in the oral cavity, one in the hypopharynx and one in the lung. Most of the esophageal cancers detected were early stage ones and they were treated mainly by endoscopic resection. Six patients had two synchronous SPMs. There were also 26 prior malignant tumors in 20 of the patients. Six patients had a multiple history of malignant tumors. The main sites of the prior tumors were the esophagus followed by the stomach and the larynx (Table 5 ). There were 9 patients with esophageal cancer, 5 with gastric cancer, 3 with laryngeal cancer, 2 with liver cancer and 2 with lung cancer. There were 5 other cancers in the colon, bladder, breast, hypopharynx and oral cavity. There were 7 metachronous SPMs in the esophagus, stomach, pancreas, lung, oral cavity and skin after treatment of the index head and neck cancers. Fig. 2 shows the frequencies of SPMs by percentage. The numbers of patients with prior malignant tumors, synchronous and metachronous SPMs were 18 (17.0%), 4 (3.8%) and 11 (10.4%), respectively, in oral cancers. The numbers of patients with prior malignant tumors, synchronous and metachronous SPMs were 18 (15.0%), 10 (8.3%) and 7 (5.8%), respectively, in laryngeal cancers. The numbers of patients with prior malignant tumors, synchronous and metachronous SPMs were 11 (22.0%), 7 (14.0%) and 4 (8.0%), respectively, in oropharyngeal cancers. The numbers of patients with prior malignant tumors, synchronous and metachronous SPMs were 20 (23.8%), 24 (28.6%) and 7 (8.3%), respectively, in hypopharyngeal cancers. Patients with hypopharyngeal cancers had synchronous SPMs very frequently and significant differences were observed between the oral cavity, larynx and oropharynx. More than 25% of the patients with hypopharyngeal cancers had synchronous SPMs and another nearly 25% of them had prior histories of malignant tumors. On the other hand, the frequencies of metachronous SPMs were not so different in these patients with cancers in the oral cavity, larynx, oropharynx and hypopharynx. We calculated the survival curves of the 106 oral, 120 laryngeal, 50 oropharyngeal and 84 hypopharyngeal cancer patients using the Kaplan-Meier method ( Fig. 3 and 4) . Twenty-three patients were omitted from this analysis because their observation times were less than 6 months. The mean and median observation times were 45.4 and 47.0 months, respectively. Fig. 3A and 3B shows the diseasespecific (index cancer specific) survival curve and the overall survival curve of patients with only the index head and neck cancer and that of patients with other multiple malignant tumors, i.e. prior malignant tumor, synchronous SPM and metachronous SPM. The 5-year disease-specific survival rate of patients with SPMs or a prior history of malignancy and that of patients without those were 71.1% and 77.8%, respectively (Fig. 3A) . Since there was no significant difference between these disease-specific survivals, it appears that the prognoses of patients with the index head and neck cancer were almost equal between these two groups. The 5-year overall survival rate of patients with SPMs or a prior history of malignancy and that of patients without those were 53.8% and 72.6%, respectively (Fig.  3B) . The overall survival rates of patients with SPMs or a prior history of malignancy were significantly poorer than that of the patients without those (p < 0.0005). Fig. 4A shows the disease-specific survival curves of patients with prior malignant tumors, synchronous and metachronous SPMs and without tumors other than the index head and neck cancers. The 5-year disease-specific survival rates of patients with prior malignant tumors, synchronous and metachronous SPMs, and without them were 70.0%, 67.2%, 88.0% and 77.8%, respectively (Fig. 4A) . The prognoses of patients with synchronous SPMs and prior malignant tumors seemed to be poorer than the prognoses of patients without them, although the differences were not significant among these curves. One patient with prior malignant tumor died 96 months after initial treatment of index head and neck cancer. This patient had a buccal cancer, which was resected at the initial treatment and recurred locally after 6 years later, and underwent re-surgery. The patient had locally recurred tumor 2 years after second surgery and died of disease. Fig. 4B shows the overall survival curves of patients with prior malignant tumors, synchronous and metachronous SPMs and without tumors other than the index head and neck cancers. The 5 year overall survival rates of patients with prior malignant tumors, synchronous and metachronous SPMs, and without them were 56.0%, 50.8%, 59.3% and 72.6%, respectively (Fig. 4B) . The prognoses of patients with synchronous and metachronous SPMs and those with prior malignant tumors were similar and seemed to be poorer than the prognoses of patients without those. There was a significant difference between the survival rate of patients with only the index head and neck cancer and that of patients with a prior history of Fig. 2 . Proportion of patients with a prior history of malignancy, synchronous and metachronous SPMs in patients with oral, laryngeal, oropharyngeal or hypopharyngeal cancers. There were significant differences between the numbers of patients with hypopharyngeal cancers who had synchronous SPMs and those of patients with oropharyngeal ( p = 0.012), laryngeal ( p = 0.003) and oral cancers ( p < 0.0001) who had synchronous SPMs. There was also a significant difference between the number of patients with a oropharyngeal cancer who had a synchronous SPM and those with oral cancer ( p = 0.046). malignancy (p < 0.005). There also was a significant difference between the survival rate of patients with only the index head and neck cancer and that of patients with a synchronous SPM (p < 0.01). As for the tumor sites of SPMs, the 5 year survival rates of patients with esophageal cancer (n = 27), gastric cancer (n = 12), lung cancer (n = 10), oral cancer (n = 10), colon cancer (n = 7), pharyngeal cancer (n = 7) and other malignancies (n = 9) were 56.7%, 62.7%, 10.0%, 46.7%, 85.7%, 85.7% and 46.9%, respectively (data not shown). Significant differences were observed between lung cancer and gastric, colon and esophageal cancers ( p < 0.05).
Discussion
We analyzed whether the incidence of patients with A: disease-specific survival curves. The 5-year survival rates of patients with only the index cancer and patients with other tumors were 77.8% and 71.1%, respectively; a significant difference was not observed between them. B: overall survival curves. The 5-year survival rates of patients with only the index cancer and patients with other tumors were 72.6% and 53.8%, respectively; there was a significant difference between them ( p < 0.0005). SPMs has been increasing or not in those who had head and neck cancers, especially oral, oropharyngeal, hypopharyngeal and laryngeal cancers, because these patients had further risk factors such as tobacco and/or alcohol use. Our results indicate that although the proportion of patients without SPMs was stable over this five-year period, those patients with synchronous SPMs had slightly increased. We considered various reasons why synchronous SPMs were increasing. One factor is the increasing number of early hypopharyngeal cancers and early esophageal cancers as SPMs. Our data indicate that patients with early hypopharyngeal cancers have a tendency to have early esophageal cancer. We think that this is due to the fact that technical progress in upper GI endoscopy and consciousnessraising of gastroenterologists have resulted in earlier diagnoses of esophageal and hypopharyngeal cancers.
Our results indicate that most synchronous SPM patients with head and neck squamous cell carcinomas were detected by upper GI endoscopic examination since approximately two-thirds (33 out of 52) of the synchronous SPMs were esophageal and gastric cancers (Table 1) . On the other hand, synchronous SPMs in the head and neck regions were about 27% (14 out of 52) and are easily detectable in routine examinations at outpatient clinics. Most of the tumors were asymptomatic and the rest of the synchronous SPMs, i.e., 4 lung cancers and a colon cancer, were detected by FDG-PET. We conclude that these two modalities, i.e., upper GI endoscopic examination and FDG-PET are convenient methods to successfully detect SPMs. FDG-PET is also useful to detect distant metastases as well as primary tumors and regional lymph node metastases and results in an accurate definition of the clinical stage of the patient. Haerle et al. (2010) reported the usefulness of FDG-PET to detect synchronous SPMs, although they compared this modality with panendoscopy and concluded that FDG-PET is superior to panendoscopy. However, as they described in their report, panendoscopy in early stage tumors is accurate enough to rule out SPMs. According to our results, upper GI endoscopic examination is sufficient to detect SPMs in our patients.
It seems that the patterns of metachronous SPMs are different in Japan and in Europe. First, in Europe, the frequencies of metachronous SPMs after the first treatment of head and neck cancers in oral and laryngeal cancer patients are more than those in pharyngeal cancer patients (Rennemo et al. 2008) . In our study, metachronous SPMs in oropharyngeal and hypopharyngeal cancer patients were as frequent as in oral and laryngeal cancer patients.
Second, the most frequent metachronous SPMs in Europe were lung cancers (Rennemo et al. 2008; Chuang et al. 2008 ), compared to upper GI tract cancers in Japan. Perhaps these results are due to the fact that less than onehalf of Japanese people have a mutant type of aldehyde dehydrogenase 2 (ALDH2) gene and are susceptible to upper GI tract cancers (Yokoyama et al. 2005; Asakage et al. 2007 ).
Our study indicates that the prognoses of patients with SPMs are significantly poorer the prognoses of patients without those. There have been several studies that examined the prognoses of patients with SPMs (Rafferty and O'Dwyer 2001; Di Martino et al. 2002; Tsou et al. 2007; Rennemo et al. 2008; Chen et al. 2010; Dequanter et al. 2011) . Those studies reported that the prognoses of patients with synchronous SPMs are significantly lower than those with metachronous SPMs and that SPMs in the esophagus or lung contribute to the poorer outcome than the other types of SPMs. In our study, the prognoses of patients with synchronous SPMs were not poorer than those with metachronous SPMs. This result may reflect the frequent early stage of esophageal cancers detected as synchronous SPMs in our patients, especially in patients with hypopharyngeal cancers. On the other hand, SPMs in the lung in our patients resulted in poorer outcomes, as described in the literature. In our study, overall survival rate of the patients with prior malignancies as well as the patients with SPMs was significantly poorer than that of the patients with only index head and neck cancer (Fig. 4B ). This may reflect the fact that these patients with multiple malignant tumors had restricted therapeutic options and in some cases the second tumors other than index cancer showed progressive disease.
The continued use of tobacco and alcohol gives rise to the risk of metachronous SPMs (Leon et al. 2009 ) and adversely affects the survival rates, with 5-year survival rates of 5% for smokers versus 20% for non-smokers, and 6% for drinkers versus 27% for non-drinkers (Schwaltz et al. 1994) . It may be critical for patients to limit their tobacco and alcohol use after the first index head and neck cancer treatment to expect better prognoses by preventing additional metachronous SPMs. There was a report describing a trend where head and neck cancer patients who continued smoking were more likely to develop tobaccorelated cancers than those who remained abstinent (Garces et al. 2007) . In this study, although the disease-specific survival rate of the patients with metachronous SPMs was as good as 88.0%, overall survival rate of them was down to 59.3%. Apparently, the metachronous SPMs such as lung cancer made the patient prognoses worse. Thus, it is crucial that the patients must continue a strict follow up to detect metachronous SPMs in their early stage after treatment of index head and neck cancer.
Although the number of patients in the present study was relatively small and the observation time has not yet been long enough, we have successfully identified the increased tendency for synchronous SPMs in head and neck cancer patients in the Sendai area and established the convenient modalities for detecting SPMs. Further studies will be needed to reveal the characteristics of metachronous SPMs in head and neck cancer patients in the future.
